Bepirovirsen

Summary

Bepirovirsen (CHEMBL4650468) is a phase-3 clinical-stage oligonucleotide; indicated across 2 conditions including hepatitis b virus infection and chronic hepatitis b virus infection.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Oligonucleotide
• Indications: 2 conditions
• Clinical trials: 14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650468
Name	Bepirovirsen
Type	Oligonucleotide
Max phase	3

Also known as: Bepirovirsen, GSK-3228836, GSK-3228836B, Gsk3228836, GSK3228836, GSK3228836B, IONIS HBVRX, ISIS 505358, ISIS-505358, ISIS-GSK3RX, BEPIROVIRSEN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
hepatitis B virus infection	3	MONDO:0005344	EFO:0004197
chronic hepatitis B virus infection	3	MONDO:0005366	EFO:0004239

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
PHASE2	7
PHASE1	4
PHASE3	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05630807	PHASE3	COMPLETED	Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)
NCT05630820	PHASE3	COMPLETED	Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)
NCT04954859	PHASE2	RECRUITING	Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
NCT06497504	PHASE2	ACTIVE_NOT_RECRUITING	Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
NCT06537414	PHASE2	ACTIVE_NOT_RECRUITING	A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
NCT04449029	PHASE2	COMPLETED	A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)
NCT04544956	PHASE2	COMPLETED	A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B
NCT04676724	PHASE2	COMPLETED	Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)
NCT05276297	PHASE2	COMPLETED	A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy
NCT05330455	PHASE1/PHASE2	TERMINATED	Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection
NCT07168356	PHASE1	ACTIVE_NOT_RECRUITING	A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease
NCT04971928	PHASE1	COMPLETED	Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment
NCT06058390	PHASE1	COMPLETED	A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants
NCT06422767	PHASE1	COMPLETED	Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).